Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Moodys
Johnson and Johnson
Express Scripts

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR OVIDREL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ovidrel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00505752 ↗ Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART) Completed Merck KGaA Phase 2 2007-01-01 This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection [IVF/ICSI]). This study will compare 3 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f® revised formulation female [RFF] Pen) in regards to the number of fertilized oocytes.
NCT00505752 ↗ Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART) Completed Merck KGaA, Darmstadt, Germany Phase 2 2007-01-01 This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection [IVF/ICSI]). This study will compare 3 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f® revised formulation female [RFF] Pen) in regards to the number of fertilized oocytes.
NCT00663416 ↗ REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients Terminated Stem Cell Therapeutics Corp. Phase 2 2008-03-01 Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control. Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients.
NCT00715364 ↗ REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients Withdrawn Stem Cell Therapeutics Corp. Phase 2 2009-08-01 To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ovidrel

Condition Name

Condition Name for Ovidrel
Intervention Trials
Infertility 12
Polycystic Ovary Syndrome 4
Stroke 3
Reproductive Behavior 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ovidrel
Intervention Trials
Infertility 13
Polycystic Ovary Syndrome 5
Syndrome 3
Stroke 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ovidrel

Trials by Country

Trials by Country for Ovidrel
Location Trials
India 12
Canada 10
United States 9
Korea, Republic of 3
China 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ovidrel
Location Trials
California 5
Virginia 2
Ohio 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ovidrel

Clinical Trial Phase

Clinical Trial Phase for Ovidrel
Clinical Trial Phase Trials
Phase 4 2
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ovidrel
Clinical Trial Phase Trials
Completed 13
Unknown status 8
Terminated 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ovidrel

Sponsor Name

Sponsor Name for Ovidrel
Sponsor Trials
University of California, San Diego 3
Merck KGaA 3
Merck KGaA, Darmstadt, Germany 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ovidrel
Sponsor Trials
Other 18
Industry 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
AstraZeneca
Boehringer Ingelheim
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.